伴有EGFR突变的非小细胞肺癌血清CYFRA21-1和CEA水平与EGFR-TKIs的疗效关系

背景与目的表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs）是EGFR基因突变晚期非小细胞癌（non-small cell lung cancer,NSCLC）患者一线标准治疗方案,但是临床实践中,疗效差异较大。本项实验拟研究治疗前血清细胞角蛋白19片段（cytokeratin-19 fragments,CYFRA21-1）和癌胚抗原（carcinoembryonic antigen,CEA）的水平是否与EGFR-TKIs疗效有关。方法回顾性分析194例EGFR基因突变...

Full description

Saved in:
Bibliographic Details
Published in中国肺癌杂志 Vol. 19; no. 8; pp. 550 - 558
Main Author 王群慧 郑华 胡范彬 张红梅 胡瑛 李杰 张同梅 刘赞 鲁葆华 胡爱民 李宝兰
Format Journal Article
LanguageChinese
Published 首都医科大学附属北京胸科医院肿瘤科, 北京,101149 2016
Subjects
CYFRA21-1
癌胚抗原
肺肿瘤
表皮生长因子受体抑制剂
癌胚抗原
Carcinoembryonic antigen
Cytokeratin 19 fragment
肺肿瘤
表皮生长因子受体抑制剂
CYFAR21-1
Lung neoplasms
Epidermal growth factor receptor-tyrosine kinase inhibitor
Online AccessGet full text

Cover

More Information
Summary:背景与目的表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs）是EGFR基因突变晚期非小细胞癌（non-small cell lung cancer,NSCLC）患者一线标准治疗方案,但是临床实践中,疗效差异较大。本项实验拟研究治疗前血清细胞角蛋白19片段（cytokeratin-19 fragments,CYFRA21-1）和癌胚抗原（carcinoembryonic antigen,CEA）的水平是否与EGFR-TKIs疗效有关。方法回顾性分析194例EGFR基因突变阳性且接受EGFR-TKIs治疗的NSCLC患者的治疗前的血清CYFRA21-1和CEA水平与EGFR-TKIs疗效及生存时间的关系。结果血清水平CYFRA21-1增高和正常的无进展生存时间（progression-free survival,PFS）分别为7.0个月和11.9个月（P〈0.001）;总生存（overall survival,OS）分别为12.6个月和28.0个月（P〈0.001）。腺癌中,血清水平增高和正常的PFS分别为7.0个月和12.0个月（P〈0.001）,OS分别为13.1个月和28.1个月（P〈0.001）。鳞癌中,血清CYFRA21-1水平高低与生存时间无关。治疗前血清CEA水平高低与生存时间无关。结论在EGFR突变肺腺癌患者,治疗前血清水平CYFRA21-1增高组EGFR-TKIs治疗的PFS和OS均较正常组短。EGFR突变肺腺癌患者,治疗前血清CYFRA21-1水平可以作为预测EGFR-TKIs治疗的疗效指标。
Bibliography:Lung neoplasms; Epidermal growth factor receptor-tyrosine kinase inhibitor; Cytokeratin 19 fragment; Carcinoembryonic antigen
12-1395/R
Background and objective Epidermal growth factor receptor-tyrosine kinase inhibitors（EGFR-TKIs） are the standard first-line treatment regimen for EGFR mutated non-small cell lung cancer（NSCLC） patients. However, the efficacy of EGFR-TKIs widely varies. The aim of this study is to determine whether the pretreatment serum cytokeratin-19 fragments（CYFRA21-1） and carcinoembryonic antigen（CEA） are associated with the efficacy of EGFR-TKIs in EGFR-mutated NSCLC patients. Methods We retrospectively enrolled 194 NSCLC patients harboring EGFR mutations who received EGFRTKIs. Clinical characteristics were collected, and the relation between the efficacy of EGFR-TKIs and pretreatment serum CYFRA21-1 and CEA was analyzed. Results In all cases, progression-free survival（PFS） in patients with high CYFRA21-1 level was significantly shorter than PFS in patients with normal CYFRA21-1（7.0 vs 11.
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2016.08.12